Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars.
Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. However, the adoption of automation in the lab setting can set the stage for a pilot phase to drive optimisation and efficiency into a new era of drug development and manufacturing. Here, Perkin Elmer highlights the ways automation is helping to improve biologics production.
Click here to listen